According to the Zhitong Finance App, Lee's Pharmaceutical Company (00950) announced its 2026 interim results, with revenue of approximately HK$797 million, up 14.6% year on year; profit attributable to company owners was HK$95.14 million, up 41.4% year on year; profit per share was HK$16.14 cents, with an interim dividend of HK3.5 per share.

Among them, revenue from imported products increased by 24.3% to approximately HK$337 million, mainly due to the contributions of “Fipley®”, “Bredinin®”, “Quintex®” and “Rui Shuyan®”. Revenue from patented and generic products increased by 8.4% to HK$459 million, mainly due to the contribution of the socazolizumab injection “Shanke Yu®” (after adding indications for treatment of extensive small cell lung cancer), “You Jing'an®”, quprostenil injection “Renier®”, azisartan tablets “Dikopin®”, and the fondazolidacin sodium injection “Lichangqing®” due to centralized dosage procurement and pricing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.